Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
NCAPH2 CAPH2
Sequence Length (AA) Molecular Weight (Da)
605 68227
Protein Name
Condensin-2 complex subunit H2
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MEDVEARFAH LLQPIRDLTK NWEVDVAAQL GEYLEELDQI CISFDEGKTT
60 70 80 90 100
MNFIEAALLI QGSACVYSKK VEYLYSLVYQ ALDFISGKRR AKQLSSVQED
110 120 130 140 150
RANGVASSGV PQEAENEFLS LDDFPDSRTN VDLKNDQTPS EVLIIPLLPM
160 170 180 190 200
ALVAPDEMEK NNNPLYSRQG EVLASRKDFR MNTCVPHPRG AFMLEPEGMS
210 220 230 240 250
PMEPAGVSPM PGTQKDTGRT EEQPMEVSVC RSPVPALGFS QEPGPSPEGP
260 270 280 290 300
MPLGGGEDED AEEAVELPEA SAPKAALEPK ESRSPQQSAA LPRRYMLRER
310 320 330 340 350
EGAPEPASCV KETPDPWQSL DPFDSLESKP FKKGRPYSVP PCVEEALGQK
360 370 380 390 400
RKRKGAAKLQ DFHQWYLAAY ADHADSRRLR RKGPSFADME VLYWTHVKEQ
410 420 430 440 450
LETLRKLQRR EVAEQWLRPA EEDHLEDSLE DLGAADDFLE PEEYMEPEGA
460 470 480 490 500
DPREAADLDA VPMSLSYEEL VRRNVELFIA TSQKFVQETE LSQRIRDWED
510 520 530 540 550
TVQPLLQEQE QHVPFDIHTY GDQLVSRFPQ LNEWCPFAEL VAGQPAFEVC
560 570 580 590 600
RSMLASLQLA NDYTVEITQQ PGLEMAVDTM SLRLLTHQRA HKRFQTYAAP
605
SMAQP

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-5922 Collapse assay details

Data source: Panorama

Official Gene Symbol
NCAPH2
Peptide Modified Sequence
FVQETELS[+79.966331]QR
Modification Type
Phospho (ST)
Protein - Site of Modification
493
Peptide - Site of Modification
8
Peptide Start
485
Peptide End
494
CPTAC ID
CPTAC-5922
Peptide Molecular Mass
1,315.5809
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Cell Lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Targeted Mass Spectrometry Enables Quantification of Novel Pharmacodynamic Biomarkers of ATM Kinase Inhibition. Whiteaker JR, Wang T, Zhao L, Schoenherr RM, Kennedy JJ, Voytovich U, Ivey RG, Huang D, Lin C, Colantonio S, Caceres TW, Roberts RR, Knotts JG, Kaczmarczyk JA, Blonder J, Reading JJ, Richardson CW, Hewitt SM, Garcia-Buntley SS, Bocik W, Hiltke T, Rodriguez H, Harrington EA, Barrett JC, Lombardi B, Marco-Casanova P, Pierce AJ, Paulovich AG. Cancers (Basel). 2021 Jul 30;13(15):3843. doi: 10.3390/cancers13153843. PMID: 34359745


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
Sciex 5500 QTRAP
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
Eksigent 425
Column Packing
Reprosil
Column Dimensions
75um x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
b2 (1+) 42.4 12.7 9 29.8 13.3 14.8 51.8 18.4 17.3 15 27 15
y8 (2+) 35.4 13.4 3.8 42.7 18.4 12.1 55.5 22.8 12.7 15 27 15
y4-98 (1+) 26.8 10.2 7.2 34.6 16 12.4 43.8 19 14.3 15 27 15
y6-98 (1+) 32.9 9.4 4.8 35.4 14.6 15.2 48.3 17.4 15.9 15 27 15
y8-98 (1+) 33.2 12.1 9.1 36.4 14.3 12.3 49.3 18.7 15.3 15 27 15
y7-98 (1+) 36.3 12.4 5.2 31.8 12.3 10.2 48.3 17.5 11.4 15 27 15
b3 (1+) 51 12 6.6 46.5 15.6 12.5 69 19.7 14.1 15 27 15
sum 11.5 5 4.4 15.8 10 11 19.5 11.2 11.8 15 27 15


Additional Resources and Comments